Pettyjohn Wood & White Inc. Acquires 165 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Pettyjohn Wood & White Inc. boosted its position in shares of iShares Biotechnology ETF (NASDAQ:IBBGet Rating) by 11.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,580 shares of the financial services provider’s stock after purchasing an additional 165 shares during the quarter. Pettyjohn Wood & White Inc.’s holdings in iShares Biotechnology ETF were worth $241,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Two Sigma Advisers LP purchased a new position in shares of iShares Biotechnology ETF in the third quarter worth approximately $64,365,000. Barclays PLC increased its position in iShares Biotechnology ETF by 25.9% in the third quarter. Barclays PLC now owns 1,626,817 shares of the financial services provider’s stock worth $263,024,000 after purchasing an additional 334,719 shares during the last quarter. Royal Bank of Canada increased its position in iShares Biotechnology ETF by 28.3% in the third quarter. Royal Bank of Canada now owns 1,328,604 shares of the financial services provider’s stock worth $214,809,000 after purchasing an additional 293,379 shares during the last quarter. Balyasny Asset Management LLC purchased a new position in iShares Biotechnology ETF during the third quarter worth $20,750,000. Finally, DeDora Capital Inc. purchased a new position in iShares Biotechnology ETF during the fourth quarter worth $24,758,000. 65.38% of the stock is currently owned by institutional investors.

Shares of IBB traded up $1.54 during trading hours on Tuesday, reaching $128.64. 76,805 shares of the company traded hands, compared to its average volume of 2,757,028. iShares Biotechnology ETF has a 12-month low of $118.60 and a 12-month high of $177.37. The stock’s fifty day moving average price is $127.99 and its 200 day moving average price is $141.62.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 30th. Investors of record on Friday, March 25th were issued a $0.118 dividend. This is an increase from iShares Biotechnology ETF’s previous quarterly dividend of $0.04. This represents a $0.47 annualized dividend and a dividend yield of 0.37%. The ex-dividend date of this dividend was Thursday, March 24th.

iShares Biotechnology ETF Profile (Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBGet Rating).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.